talzenna
pfizer europe ma eeig - talazoparib - nowotwory piersi - Środki przeciwnowotworowe - talzenna jest wskazany w monoterapii w leczeniu dorosłych pacjentów z embrionalna linii genów brca1/2 mutacje, które mają her2-ujemnego miejscowo zaawansowanym lub przerzutowym rakiem piersi . patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. pacjenci z receptorem hormonu (h)-dodatni rak piersi muszą być przetworzone do эндокринно-terapia, lub uważane za nieodpowiednie dla dokrewnego na podstawie.
efmody
diurnal europe b.v. - hydrokortyzon - adrenal hyperplasia, congenital - kortykosteroidy do stosowania systemowego - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rywaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Środki przeciwzakrzepowe - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
modigraf
astellas pharma europe b.v. - takrolimus - odrzucenie wniosku - leki immunosupresyjne - profilaktyka odrzucenia przeszczepu u biorców aloprzeszczepów dorosłych i dzieci, nerek, wątroby lub serca. i pediatrycznych pacjentów leczenie odrzucenia opornych na leczenie innych leków immunosupresyjnych u dorosłych .
varlota 25 mg tabletki powlekane
alvogen pharma trading europe eood - erlotinibum - tabletki powlekane - 25 mg
varlota 50 mg tabletki powlekane
alvogen pharma trading europe eood - erlotinibum - tabletki powlekane - 50 mg
varlota 100 mg tabletki powlekane
alvogen pharma trading europe eood - erlotinibum - tabletki powlekane - 100 mg
varlota 150 mg tabletki powlekane
alvogen pharma trading europe eood - erlotinibum - tabletki powlekane - 150 mg
lorviqua
pfizer europe ma eeig - lorlatinib - rak, niedrobnokomórkowe płuca - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
daurismo
pfizer europe ma eeig - glasdegib maleate - białaczka, szpikowe, ostre - Środki przeciwnowotworowe - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.